Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, outlines the ‘use via early access to ixazomib’ (uvea-ixa) study which investigated ixazomib-based therapy in relapsed/refractory multiple myeloma (MM) patients treated via an early access program in Europe. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).